{"id":"topical-clindamycin","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin irritation or dryness"},{"rate":null,"effect":"Contact dermatitis"},{"rate":null,"effect":"Erythema"},{"rate":null,"effect":"Peeling or scaling"}]},"_chembl":null,"_dailymed":{"setId":"c8fe61f1-f3c5-4452-9980-a727461b9844","title":"CLINDAMYCIN PHOSPHATE (CLINDAMYCIN PHOSPHATE TOPICAL) SOLUTION [CARNEGIE PHARMACEUTICALS, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clindamycin binds to the bacterial 50S ribosomal subunit and inhibits peptide bond formation, preventing bacterial protein synthesis. When applied topically, it reduces the population of Propionibacterium acnes and other bacteria on the skin surface, thereby reducing inflammation and comedone formation. This makes it effective for treating acne and other bacterial skin infections.","oneSentence":"Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T06:29:20.200Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"},{"name":"Bacterial skin infections"},{"name":"Rosacea (off-label)"}]},"trialDetails":[{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":300},{"nctId":"NCT07421804","phase":"NA","title":"Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel)","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-04","conditions":"Acne Vulgaris","enrollment":50},{"nctId":"NCT07392047","phase":"PHASE4","title":"Metronidazole 2% Gel Versus Clindamycin 1% Gel for Moderate Acne Vulgaris","status":"NOT_YET_RECRUITING","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2026-02","conditions":"Acne Vulgaris","enrollment":60},{"nctId":"NCT07205107","phase":"","title":"Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris","status":"RECRUITING","sponsor":"Bausch Health Americas, Inc.","startDate":"2025-10-02","conditions":"Acne Vulgaris","enrollment":200},{"nctId":"NCT05582434","phase":"EARLY_PHASE1","title":"Experience With Topical Acne Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2024-02-15","conditions":"Acne","enrollment":72},{"nctId":"NCT04104178","phase":"PHASE3","title":"Optimal Treatment of MRSA Throat Carriers","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2020-05-20","conditions":"MRSA, MRSA Colonization","enrollment":53},{"nctId":"NCT04469075","phase":"PHASE2","title":"Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-07-09","conditions":"Glioblastoma, Recurrent Glioblastoma, Skin Toxicity","enrollment":48},{"nctId":"NCT03935828","phase":"PHASE2","title":"Effect of Topical Sinonasal Antibiotics","status":"WITHDRAWN","sponsor":"United States Naval Medical Center, San Diego","startDate":"2019-06","conditions":"Chronic Rhinosinusitis (Diagnosis), Antibiotic Side Effect","enrollment":""},{"nctId":"NCT06925386","phase":"PHASE2","title":"The Relationship Between Microbioma Balance and Acne Vulgaris as a New Acne Treatment","status":"NOT_YET_RECRUITING","sponsor":"Universitas Padjadjaran","startDate":"2025-05-01","conditions":"Acne Vulgaris","enrollment":64},{"nctId":"NCT04321070","phase":"PHASE1","title":"Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2019-09-09","conditions":"Acne Vulgaris","enrollment":550},{"nctId":"NCT05849090","phase":"EARLY_PHASE1","title":"Vancomycin and Tobramycin Powder Use in Acute Open Fractures","status":"COMPLETED","sponsor":"University of Utah","startDate":"2023-03-27","conditions":"Infections","enrollment":10},{"nctId":"NCT06673641","phase":"PHASE1","title":"A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2024-05-13","conditions":"Acne Vulgaris","enrollment":382},{"nctId":"NCT01044264","phase":"NA","title":"Clinical Study Between Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2007-12","conditions":"Acne Vulgaris","enrollment":602},{"nctId":"NCT05926869","phase":"PHASE2","title":"Comparison of the Efficacy of Clindamycin Phosphate 1% Gel Versus Once-daily Dapsone 5% Gel in the Treatment of Moderate Acne Vulgaris","status":"COMPLETED","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2022-08-01","conditions":"Acne Vulgaris","enrollment":100},{"nctId":"NCT05762484","phase":"NA","title":"Efficacy of Laser Hair Removal Therapy in HS","status":"NOT_YET_RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2023-04","conditions":"Hidradenitis Suppurativa, Acne Inversa","enrollment":58},{"nctId":"NCT01874860","phase":"PHASE2","title":"Skin Rash Study Before Chemotherapy in Colorectal & Head and Neck Cancer Patients","status":"COMPLETED","sponsor":"University of Louisville","startDate":"2013-08","conditions":"Colorectal Cancer, Head and Neck Cancer","enrollment":24},{"nctId":"NCT01063270","phase":"NA","title":"Trial Comparing Efficacy of Treatments for Hidradenitis Suppurativa","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2010-02","conditions":"Hidradenitis Suppurativa","enrollment":18},{"nctId":"NCT03173053","phase":"NA","title":"S. Aureus Decolonization in HPN Patients.","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2018-02-08","conditions":"Staphylococcus Aureus, Motility Disorder","enrollment":63},{"nctId":"NCT01796665","phase":"PHASE3","title":"A Study to Compare Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2012-02","conditions":"Acne","enrollment":1180},{"nctId":"NCT01138514","phase":"PHASE3","title":"Clinical Study Between Two Clindamycin 1%/Benzoyl Peroxide 5% Topical Gels","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2009-10","conditions":"Acne Vulgaris","enrollment":1555},{"nctId":"NCT03779360","phase":"NA","title":"Intradermal LPS and Antibiotics","status":"COMPLETED","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2018-10-12","conditions":"Inflammation; Skin","enrollment":32},{"nctId":"NCT03717506","phase":"PHASE3","title":"Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Balmoral Medical company","startDate":"2018-10-10","conditions":"Acne Vulgaris","enrollment":1236},{"nctId":"NCT04584840","phase":"NA","title":"Initial Management of MRONJ Stages I and II, a Clinical Trial With Detection of Salivary Biomarkers","status":"UNKNOWN","sponsor":"Fundació d'investigació Sanitària de les Illes Balears","startDate":"2020-11-01","conditions":"Osteonecrosis of the Jaw, Bisphosphonate Induced, Osteonecrosis of the Jaw, Bisphosphonate Related","enrollment":50},{"nctId":"NCT03522441","phase":"PHASE3","title":"Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Akorn, Inc.","startDate":"2018-04-27","conditions":"Acne Vulgaris","enrollment":1125},{"nctId":"NCT04118296","phase":"PHASE1, PHASE2","title":"Decreasing Severity of Acne Vulgaris After the Use of a Combination of Anti-Acne Cream","status":"COMPLETED","sponsor":"Sukma Skin Treatment","startDate":"2019-10-08","conditions":"Acne Vulgaris","enrollment":150},{"nctId":"NCT02616614","phase":"PHASE3","title":"Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2015-05","conditions":"Acne Vulgaris","enrollment":862},{"nctId":"NCT03257202","phase":"PHASE2","title":"Topical Treatment and Prevalence of P. Acnes","status":"COMPLETED","sponsor":"University of Southern California","startDate":"2017-09-11","conditions":"Surgical Site Infection","enrollment":12},{"nctId":"NCT01951768","phase":"PHASE4","title":"Efficacy and Safety of Garamycin® Sponge in Diabetic Patients With a Moderate or Severe Foot Ulcer Infection","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2013-09","conditions":"Diabetic Foot Ulcer","enrollment":88},{"nctId":"NCT04134273","phase":"PHASE1","title":"Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2019-03-20","conditions":"Acne Vulgaris","enrollment":1260},{"nctId":"NCT01237821","phase":"NA","title":"Comparing OTC Acne Treatment to Prescription Regimen","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2010-10","conditions":"Acne Vulgaris","enrollment":66},{"nctId":"NCT03883269","phase":"PHASE4","title":"Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients","status":"RECRUITING","sponsor":"Centre for Human Drug Research, Netherlands","startDate":"2018-03-20","conditions":"Acne Vulgaris","enrollment":30},{"nctId":"NCT02731105","phase":"PHASE4","title":"Pilot Study of Tolerability and Effectivity of Two Combination Topical Acne Products","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2015-02","conditions":"Acne Vulgaris","enrollment":22},{"nctId":"NCT01047189","phase":"PHASE4","title":"Adherence to Study Medication Compared to Generic Topical Clindamycin Plus Generic Topical Tretinoin in Subjects With Mild to Moderate Acne Vulgaris","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2009-03","conditions":"Acne Vulgaris","enrollment":26},{"nctId":"NCT03238469","phase":"NA","title":"Microwave Ablation in Mild Axillary Hidradenitis Suppurativa","status":"TERMINATED","sponsor":"M.B.A. van Doorn","startDate":"2017-09-01","conditions":"Hidradenitis Suppurativa, Acne Inversa","enrollment":9},{"nctId":"NCT01445301","phase":"PHASE3","title":"Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-09-27","conditions":"Acne Vulgaris","enrollment":800},{"nctId":"NCT02674191","phase":"NA","title":"Posterior Segment Intrusion Using Miniplates","status":"UNKNOWN","sponsor":"Manal El Namrawy","startDate":"2016-05","conditions":"Orthodontic Anchorage Procedures","enrollment":24},{"nctId":"NCT03412071","phase":"NA","title":"Effect of Antibiotics on Penile Microbiome and HIV Susceptibility Study in Ugandan Men","status":"UNKNOWN","sponsor":"University of Toronto","startDate":"2017-12-07","conditions":"Foreskin HIV Susceptibility","enrollment":125},{"nctId":"NCT01948570","phase":"","title":"Clinical Study for the Evaluation of P-3075 Cream on Acne Treatment","status":"COMPLETED","sponsor":"Derming SRL","startDate":"2013-03","conditions":"Acne","enrollment":40},{"nctId":"NCT02058628","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Clindamycin + Benzoyl Peroxide Formulation With Azelaic Acid Formulation in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-02-21","conditions":"Acne Vulgaris","enrollment":222},{"nctId":"NCT01269541","phase":"NA","title":"MESS-study MRSA Eradication Study Skåne","status":"COMPLETED","sponsor":"Region Skane","startDate":"2011-03-01","conditions":"Throatcarriers of MRSA","enrollment":69},{"nctId":"NCT00757523","phase":"PHASE4","title":"Evaluation of the Effectiveness, Safety, and Tolerability of Duac Akne Gel and Epiduo Gel in the Treatment of Facial Acne Vulgaris","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2008-09-10","conditions":"Acne Vulgaris","enrollment":382},{"nctId":"NCT02465632","phase":"PHASE3","title":"To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2015-04","conditions":"Acne Vulgaris","enrollment":1100},{"nctId":"NCT01132443","phase":"PHASE1","title":"W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2010-05-06","conditions":"Acne Vulgaris","enrollment":72},{"nctId":"NCT00964366","phase":"PHASE4","title":"Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-07","conditions":"Acne Vulgaris","enrollment":53},{"nctId":"NCT00689117","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2008-04","conditions":"Acne Vulgaris, Acne","enrollment":1649},{"nctId":"NCT00841776","phase":"PHASE4","title":"Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2007-08","conditions":"Acne","enrollment":54},{"nctId":"NCT00891982","phase":"PHASE3","title":"A Clinical Study to Evaluate the Tolerability of a Topical Antibiotic and Retinoid Used in a Combined Regimen With a BPO Wash","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-04-01","conditions":"Acne Vulgaris","enrollment":60},{"nctId":"NCT02595034","phase":"PHASE1","title":"A Study CLBG and Benzoyl Peroxide Gel 1%/5% to BenzaClin® Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2015-01","conditions":"Acne Vulgaris","enrollment":1000},{"nctId":"NCT00473083","phase":"PHASE2","title":"Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer","status":"COMPLETED","sponsor":"British Columbia Cancer Agency","startDate":"2009-01","conditions":"Rash","enrollment":150},{"nctId":"NCT01015638","phase":"PHASE4","title":"Compare the Tolerance of Clindamycin 1% /Benzoyl Peroxide (BPO) 5% Gel to Clindamycin 1.2%/ BPO 2.5% Topical Medications","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-08","conditions":"Acne Vulgaris","enrollment":36},{"nctId":"NCT00887484","phase":"PHASE4","title":"A Comparative Study of the Tolerability of Two Combination Therapies for the Treatment of Acne","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-02","conditions":"Acne Vulgaris","enrollment":50},{"nctId":"NCT00964223","phase":"PHASE4","title":"A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-07","conditions":"Acne Vulgaris","enrollment":28},{"nctId":"NCT00332163","phase":"PHASE2","title":"Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-04","conditions":"Metastatic Colorectal Cancer, Skin Rash, Skin Toxicities","enrollment":95},{"nctId":"NCT00926367","phase":"PHASE4","title":"Two-week Study to Compare the Tolerance and Irritation Potential of Two Combination Topical Gel Acne Medications","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-05","conditions":"Acne Vulgaris","enrollment":52},{"nctId":"NCT01400932","phase":"PHASE3","title":"Study STF115288, a Clinical Confirmation Study of GI148512 in the Treatment of Acne Vulgaris in Japanese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-07","conditions":"Acne Vulgaris","enrollment":360},{"nctId":"NCT01769664","phase":"PHASE1","title":"A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2012-09","conditions":"Acne Vulgaris","enrollment":650},{"nctId":"NCT01788384","phase":"PHASE3","title":"Evaluate Therapeutic Equivalence and Safety of Two Clindamycin Phosphate and Benzoyl Peroxide Gels in Acne Vulgaris","status":"COMPLETED","sponsor":"Watson Laboratories, Inc.","startDate":"2012-07","conditions":"Acne Vulgaris","enrollment":708},{"nctId":"NCT01697826","phase":"PHASE4","title":"Comparison of Two Topical Formulations Containing Clindamycin and Clotrimazole in Patients With Vaginal Infections","status":"COMPLETED","sponsor":"Dr Bharti Daswani","startDate":"2011-04","conditions":"Vaginal Infections","enrollment":73},{"nctId":"NCT01231334","phase":"PHASE4","title":"A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-08","conditions":"Acne Vulgaris","enrollment":286},{"nctId":"NCT00807014","phase":"PHASE4","title":"Evaluation of Quality of Life, Efficacy, and Tolerance of Duac® Gel Compared to Differin® Gel in the Treatment of Acne","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2006-11","conditions":"Acne Vulgaris","enrollment":169},{"nctId":"NCT01206348","phase":"PHASE4","title":"Combination Treatment for Moderate to Severe Acne","status":"COMPLETED","sponsor":"Medicis Global Service Corporation","startDate":"2010-09","conditions":"Acne","enrollment":97},{"nctId":"NCT00219570","phase":"PHASE4","title":"Dalacin-T Gel Post Approval Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-01","conditions":"Acne Vulgaris","enrollment":134},{"nctId":"NCT01257906","phase":"NA","title":"Bioequivalence Study Comparing Clindamycin Phosphate (1.2%) and Tretinoin (0.025%) Topical Gel to Ziana and Placebo","status":"COMPLETED","sponsor":"Actavis Mid-Atlantic LLC","startDate":"2010-05","conditions":"MILD TO SEVERE ACNE VULGARIS","enrollment":1225},{"nctId":"NCT01052246","phase":"NA","title":"Pulsed Dye Laser Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Laserklinik Karlsruhe","startDate":"2008-10","conditions":"Acne Vulgaris","enrollment":80},{"nctId":"NCT00664248","phase":"PHASE3","title":"A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris","status":"COMPLETED","sponsor":"Dow Pharmaceutical Sciences","startDate":"2006-10","conditions":"Acne Vulgaris","enrollment":1414},{"nctId":"NCT00663286","phase":"PHASE3","title":"A Clinical Trial Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris","status":"COMPLETED","sponsor":"Dow Pharmaceutical Sciences","startDate":"2006-10","conditions":"Acne Vulgaris","enrollment":1399},{"nctId":"NCT00361322","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of a Preparation Containing an Antibiotic and Anti-Inflammatory Agent in Acne Vulgaris","status":"COMPLETED","sponsor":"Hadassah Medical Organization","startDate":"2005-04","conditions":"Acne Vulgaris","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":183,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dalacin cream 2%"],"phase":"marketed","status":"active","brandName":"Topical Clindamycin","genericName":"Topical Clindamycin","companyName":"University of Toronto","companyId":"university-of-toronto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Used for Acne vulgaris, Bacterial skin infections, Rosacea (off-label).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}